Hemophagocytic Lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma
Kenworthy C, Di M, Deshpande H. Hemophagocytic Lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma. Current Problems In Cancer Case Reports 2022, 8: 100202. DOI: 10.1016/j.cpccr.2022.100202.Peer-Reviewed Original ResearchNatural killer (NK) cell activityImmune checkpoint inhibitor therapyImmune checkpoint inhibitor useSoluble IL-2 receptorCheckpoint inhibitor useImmune checkpoint inhibitorsCheckpoint inhibitor therapyCoffee-ground emesisIL-2 receptorPelvic osteosarcomaCheckpoint inhibitorsElevated ferritinInhibitor therapyHemophagocytic lymphohistiocytosisMetastatic sarcomaFailed treatmentElevated triglyceridesInhibitor useSarcoma patientsConventional therapyCell activationCancer treatmentPatientsSarcomaTherapy